ABVD versus BEACOPP for Hodgkin's lymphoma

New England Journal of Medicine

Volumn 365, Issue 16, 2011, Pages 1544-1546

  Tam, Constantine S ^a   Herschtal, Alan ^b   Seymour, John F ^b  

^a ST VINCENT S HOSPITAL   (Australia)

^b PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

ADVANCED CANCER; CANCER COMBINATION CHEMOTHERAPY; CONFIDENCE INTERVAL; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; HODGKIN DISEASE; HUMAN; LETTER; OVERALL SURVIVAL; PRIORITY JOURNAL; SURVIVAL RATE; TREATMENT RESPONSE;

EID: 80054763462     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1109618     Document Type: Letter

References (3)

1. Viviani S, Zinzani PL, Rambaldi A, et al. ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned. N Engl J Med 2011;365:203-12.
2. Diehl V, Franklin J, Pfreundschuh M, et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med 2003;348: 2386-95. [Erratum, N Engl J Med 2005;353:744.] (Pubitemid 36682817)
3. Engert A, Diehl V, Franklin J, et al. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study. J Clin Oncol 2009;27:4548-54.